Kwashiorkor

Summary

Kwashiorkor (MONDO:0006826) is a disease and 14 clinical trials. Top therapeutic interventions include amoxicillin, albendazole, and cefdinir. A subtype of protein-energy malnutrition — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 14

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	kwashiorkor
Mondo ID	MONDO:0006826
EFO	EFO:1001009
MeSH	D007732
DOID	DOID:13579
ICD-10-CM	E40
ICD-11	1656486805
SNOMED CT	58262005
UMLS	C0022806
MedGen	7233
MedDRA	10023504
Is cancer (heuristic)	no

Also known as: nutritional edema with dyspigmentation of skin and/or hair · nutritional oedema with dyspigmentation of skin and hair

Disease family

This is a subtype of protein-energy malnutrition. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › nutritional disorder › nutritional deficiency disease › protein-energy malnutrition › kwashiorkor

Related subtypes (1): marasmus

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 14.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	14

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06154174	Not specified	RECRUITING	Choline to Improve Malnutrition and Enhance Cognition
NCT06869850	Not specified	RECRUITING	Milk Fat Globule Membrane-Enhanced RUTF for Children With Severe Acute Malnutrition
NCT00069134	Not specified	COMPLETED	Study of Antioxidants and Oxidants in Malnourished Children
NCT00429351	Not specified	COMPLETED	Aromatic Amino Acid Metabolism in the Pathogenesis of Kwashiorkor
NCT01000298	Not specified	COMPLETED	Effectiveness of Oral Antibiotics in the Treatment of Severe Acute Malnutrition
NCT01395381	Not specified	WITHDRAWN	Effectiveness of Oral Albendazole in the Treatment of Severe Acute Malnutrition
NCT01529125	Not specified	COMPLETED	Safety and Metabolic Study of Highly Active Antiretroviral Therapy (HAART) in Malnourished Children With HIV
NCT01790815	Not specified	COMPLETED	Mothers Understand And Can do it - Mid Upper Arm Circumference Screening for Malnutrition Performed by Mothers
NCT02053857	Not specified	COMPLETED	Pilot Study of PUFA-optimized RUTF for Severe Acute Malnutrition
NCT02413905	Not specified	COMPLETED	Characterizing the Gut Microbiota Alteration Associated With Severe Acute Malnutrition
NCT03520621	Not specified	COMPLETED	The Role of Sulfur Amino Acids in Risk of Kwashiorkor
NCT05009823	Not specified	COMPLETED	Dietary Rehabilitation in Severely Acutely Malnourished Children
NCT05015257	Not specified	COMPLETED	Effectiveness of Four Transition Dietary Regimens in the Hospital Management of Children With Kwashiorkor.
NCT05020847	Not specified	COMPLETED	Effectiveness of Alternative Diets During the Stabilization Phase on Children With Complicated SAM

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
AMOXICILLIN	4	4
ALBENDAZOLE	4	1
CEFDINIR	4	1
SULFADOXINE	4	1